Check whether envafolimab plus lenvatinib helps advanced uterine cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests whether envafolimab alone or combined with lenvatinib can slow or shrink advanced endometrial (uterine) cancer. It’s for people whose cancer has grown again or spread and who didn’t do well with standard platinum chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign the informed consent form and agree to study procedures.
- You have confirmed advanced or metastatic endometrial cancer that can’t be cured with surgery or radiation.
- Your cancer got worse or you couldn’t tolerate first-line platinum chemotherapy (with a rule about relapse within 12 months).
- You have at least one measurable tumor spot on scans (RECIST 1.1), confirmed by an independent imaging review.
- Your general health is good enough (ECOG performance status 0 or 1) and you’re expected to live at least 12 weeks.
- You must have usable tumor tissue available (archived or new biopsy) for biomarker testing before starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a repurposed drug to the standard combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) can help treat advanced or recurrent endometrial cancer. It is for people whose cancer has returned or progressed after platinum chemotherapy and who are not suitable for curative surgery or radiation.
This study tests whether adding another drug to the standard combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) can help treat advanced or recurrent endometrial cancer that has already progressed after platinum-based chemotherapy. If you qualify, you may have access to a new treatment option while helping doctors learn what works best.
This trial tests envafolimumab, an immune therapy given alone, in people with advanced solid tumors that can’t be removed by surgery or have spread. It’s for patients whose cancer has grown despite (or they couldn’t tolerate) standard treatment, and it aims to find whether this drug can shrink tumors or slow growth.
This trial tests a new medicine called QL1706 (a type of immunotherapy that helps your immune system fight cancer) combined with chemotherapy for women with advanced or recurrent endometrial cancer that has not been treated before. The goal is to see if this combination can shrink tumors and help you live longer.
This trial tests a combination of immunotherapy (adebrelimab) and chemotherapy (carboplatin/paclitaxel), followed by more immunotherapy, with or without an additional targeted drug (apatinib), for advanced or recurrent endometrial cancer. It aims to see if adding the targeted drug improves outcomes.
This trial studies whether combining envafolimab (an anti-immune cancer medicine) with lenvatinib (a targeted pill) can shrink or control advanced cancers that have stopped responding to standard care. It may help people whose tumors are not curable with usual treatments, by testing a new combo and finding safe doses.
Hear when a new Advanced Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.